About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDNCT00707629

Long Term Effects of Diabetes of Very Young Children

To investigate neurocognitive and behavioral measures in 25 children aged 6-10 years diagnosed with diabetes for \> 5 years who have received long-term insulin pump therapy (\> 3 years) compared to a ...

Lead sponsor: Indiana University•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Indiana University

Collaborators

Juvenile Diabetes Research Foundation

Age

6 - 10 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Subjects must have type 1 diabetes for at least 5 years, diagnosed prior to the age of 5 years
•Children recruited on pumps must have used pump therapy for at least 3 years
•Parents/guardians must be understand the protocol and be able to give consent, with assent obtained from all children over the age of 7 years.

Exclusion Criteria

•Children will be excluded if they have additional medical problems requiring treatment with agents known to affect blood glucose such as steroids or L-asparaginase.
•Children must not have any other chronic illness in addition to diabetes with the exception of treated autoimmune hypothyroidism.

Related studies

Primary Care Pragmatic, Real World Experience for Automated Insulin Delivery

NCT07011147 · Type 1 Diabetes (T1D), Type 2 Diabetes, and more

Automated Insulin for Management of Intrapartum Glycemia

NCT06883344 · Type 1 Diabetes (T1D), Pregnancy, and more

RECRUITINGPhase 2

INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes

NCT07224321 · Type 1 Diabetes Mellitus

Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs)

NCT07457580 · Type 1 Diabetes

Long-Term Outcomes of Teplizumab in Routine Clinical Care

NCT07360080 · Type 1 Diabetes

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: March 1, 2016Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment25

Start dateAug 2005

Last updatedMar 1, 2016

Condition

Type 1 Diabetes

Locations shown

Riley Hospital for Children

Indianapolis, Indiana

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 1, 2016Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions